Overview

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
National Cancer Institute (NCI)
Treatments:
Doxorubicin
Liposomal doxorubicin
Motexafin gadolinium